英格兰紧急疑似癌症转诊后未发现癌症者的未来癌症风险:一项全国队列研究
转诊后1-5年后续癌症绝对发生率为每10万转诊者年1338例,高于预期1054例(SIR 1.27,95%CI 1.26-1.28)。
要点
- 转诊后1年内未发现癌症者,1-5年后续癌症发生率高于同期英格兰预期水平(SIR 1.27)。
- 乳腺路径后续任何癌症绝对发生率最低(746/10万转诊者年),泌尿路径最高(2110/10万转诊者年)。
- 头颈路径随后发生与初始转诊同一癌症的相对风险最高(SIR 3.49),肺路径次之(SIR 3.00)。
核心结论
- 紧急疑似癌症转诊后5年内癌症风险高于预期。
- 作者认为应研究主动监测、安全网及癌症意识或风险降低等针对性干预的潜力。
研究设计与样本
- 全国队列研究,使用英格兰癌症等待时间数据集中的紧急疑似癌症转诊数据,并链接国家癌症登记数据集中的癌症诊断数据。
- 提取2013年4月1日至2014年3月31日八条最常见紧急疑似癌症转诊路径(乳腺、妇科、头颈、下消化道、上消化道、肺、皮肤、泌尿)的数据,对转诊后1年内未诊断癌症者随访5年。
- 主要目标为调查紧急疑似癌症转诊后1年内未发现癌症者中,转诊后1-5年后续癌症的发生及类型,总体及按八条路径分别分析。
- 将后续癌症数量与转诊后1-5年预期癌症发病率比较,使用基于同期英格兰匹配年龄-性别分布的标准化发病比(SIR)。
- 分析按转诊组分层重复,并计算所有癌症及与初始转诊同一癌症的绝对率和预期率。
主要发现
- 转诊后1-5年任何后续癌症诊断的绝对率在疑似乳腺癌转诊后最低(每10万转诊者年746例[728-763]),在疑似泌尿系(2110例[2070-2150])或肺癌(1835例[1767-1906])转诊后最高。
- 对于与初始转诊路径同一癌症的诊断,绝对率最高为泌尿路径(每10万转诊者年1011例[984-1039])和肺路径(638例[598-680])。
- 随后诊断与初始转诊路径同一癌症的相对风险最高为头颈路径(SIR 3.49[95%CI 3.22-3.78])和肺路径(SIR 3.00[2.82-3.20])。
临床怎么用
- 作者认为应研究主动监测、安全网及癌症意识或风险降低等针对性干预的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following referral for investigation of urgent suspected cancer within the English National Health Service referral system, 7% of referred individuals are diagnosed with cancer. This study aimed to investigate the risk of cancer occurrence within 1-5 years of finding no cancer following an urgent suspected cancer referral. METHODS: This national cohort study used urgent suspected cancer referral data for England from the Cancer Waiting Times dataset and linked it with cancer diagnosis data from the National Cancer Registration dataset. Data were extracted for the eight most commonly referred to urgent suspected cancer referral pathways (breast, gynaecological, head and neck, lower and upper gastrointestinal, lung, skin, and urological) for the period April 1, 2013, to March 31, 2014, with 5-year follow-up for individuals with no cancer diagnosis within 1 year of referral. The primary objective was to investigate the occurrence and type of subsequent cancer in years 1-5 following an urgent suspected cancer referral when no cancer was initially found, both overall and for each of the eight referral pathways. The numbers of subsequent cancers were compared with expected cancer incidence in years 1-5 following referral, using standardised incidence ratios (SIRs) based on matched age-gender distributions of expected cancer incidence in England for the same time period. The analysis was repeated, stratifying by referral group, and by calculating the absolute and expected rate of all cancers and of the same individual cancer as the initial referral. FINDINGS: Among 1·18 million referrals without a cancer diagnosis in years 0-1, there were 63 112 subsequent cancers diagnosed 1-5 years post-referral, giving an absolute rate of 1338 (95% CI 1327-1348) cancers per 100 000 referrals per year (1038 [1027-1050] in females, 1888 [1867-1909] in males), compared with an expected rate of 1054 (1045-1064) cancers per 100 000 referrals per year (SIR 1·27 [95% CI 1·26-1·28]). The absolute rate of any subsequent cancer diagnosis 1-5 years after referral was lowest following suspected breast cancer referral (746 [728-763] cancers per 100 000 referrals per year) and highest following suspected urological (2110 [2070-2150]) or lung cancer (1835 [1767-1906]) referral. For diagnosis of the same cancer as the initial referral pathway, the highest absolute rates were for the urological and lung pathways (1011 [984-1039] and 638 [598-680] cancers per 100 000 referrals per year, respectively). The highest relative risks of subsequent diagnosis of the same cancer as the initial referral pathway were for the head and neck pathway (SIR 3·49 [95% CI 3·22-3·78]) and lung pathway (3·00 [2·82-3·20]). INTERPRETATION: Cancer risk was higher than expected in the 5 years following an urgent suspected cancer referral. The potential for targeted interventions, such as proactive monitoring, safety-netting, and cancer awareness or risk reduction initiatives should be investigated. FUNDING: Cancer Research UK.
引用
- Scott SE, Gildea C, Nicholson BD, et al. Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study. Lancet Oncol. 2023. PMID: 37922929. doi:10.1016/S1470-2045(23)00435-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。